PRINCETON, N.J., June 3 /PRNewswire/ -- Celator Pharmaceuticals reported positive results from its CPX-1 Phase 2 clinical trial in patients with advanced colorectal cancer. CPX-1 is a liposomal ...
Initial evidence of CPX-351 activity in patients younger than 60 years emerged from a phase I trial [1]; however, subsequent pivotal phase III trial focused on older patients (≥60 years), where ...
The liposomal dual-drug formulation of daunorubicin and cytarabine, CPX-351, has become the preferred induction therapy for most patients with therapy-related acute myeloid leukemia (t-AML, now termed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results